CellCentric
Private Company
Total funding raised: $234M
Overview
CellCentric is a UK-based, private biotech founded in 2004, focused on inhibiting the epigenetic targets p300 and CBP for oncology. Its lead candidate, inobrodib, is a first-in-class, oral small molecule currently in clinical trials for multiple myeloma, with promise in other cancers. The company emphasizes a collaborative R&D model and aims to deliver a convenient, community-based treatment option to improve patient access and quality of life. CellCentric is led by an experienced team of drug developers and is backed by investor directors on its board.
Technology Platform
Epigenetic drug discovery platform focused on first-in-class, oral small molecule inhibitors of the p300 and CBP bromodomains. The platform leverages selective displacement of these transcription co-activators from chromatin to downregulate key oncogenes like MYC and IRF4.
Funding History
5Opportunities
Risk Factors
Competitive Landscape
Inobrodib is a first-in-class p300/CBP inhibitor, placing it in a novel but emerging competitive niche within epigenetic oncology. It faces indirect competition from other epigenetic modulators (e.g., BET inhibitors) and direct competition from other early-stage p300/CBP programs. Its most significant competition comes from the crowded landscape of approved and pipeline therapies for multiple myeloma, including bispecific antibodies, CAR-T therapies, and other targeted agents.